Search

Your search keyword '"Kostic, Ana"' showing total 31 results
Start Over "Kostic, Ana" Publication Type Magazines
31 results on '"Kostic, Ana"'

1. OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL

Author

Linhares, Yuliya, Freytes, Cesar O., Cherry, Mohamad, Bachier, Carlos, Maris, Michael, Hoda, Daanish, Varela, Juan C., Bellomo, Courtney, Cross, Scott, Essell, James, Fanning, Suzanne, Terebelo, Howard, Yimer, Habte, Courtright, Jay, Sharman, Jeff P., Kostic, Ana, Vedal, Min, Ogasawara, Ken, Avilion, Ariel, Espinola, Ricardo, Yuan, Brenda, and Mattar, Bassam

Abstract

•Liso-cel treatment at community sites with outpatient or inpatient monitoring demonstrated high, durable responses and manageable safety.•Liso-cel treatment in the community setting with outpatient monitoring is feasible in appropriate patients using standard procedures.

Published
2024
Full Text
View/download PDF

2. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Author

Abramson, Jeremy S., Palomba, M. Lia, Gordon, Leo I., Lunning, Matthew, Wang, Michael, Arnason, Jon, Purev, Enkhtsetseg, Maloney, David G., Andreadis, Charalambos, Sehgal, Alison, Solomon, Scott R., Ghosh, Nilanjan, Dehner, Christine, Kim, Yeonhee, Ogasawara, Ken, Kostic, Ana, and Siddiqi, Tanya

Abstract

•Pivotal TRANSCEND NHL 001 study demonstrated the efficacy and safety of liso-cel as third-line or later treatment for patients with R/R LBCL.•With 2-year follow-up, liso-cel showed high response rates, durable remissions, and a manageable safety profile for patients with R/R LBCL.

Published
2024
Full Text
View/download PDF

3. Regulation of cell distancing in peri-plaque glial nets by Plexin-B1 affects glial activation and amyloid compaction in Alzheimer’s disease

Author

Huang, Yong, Wang, Minghui, Ni, Haofei, Zhang, Jinglong, Li, Aiqun, Hu, Bin, Junqueira Alves, Chrystian, Wahane, Shalaka, Rios de Anda, Mitzy, Ho, Lap, Li, Yuhuan, Kang, Sangjo, Neff, Ryan, Kostic, Ana, Buxbaum, Joseph D., Crary, John F., Brennand, Kristen J., Zhang, Bin, Zou, Hongyan, and Friedel, Roland H.

Abstract

Communication between glial cells has a profound impact on the pathophysiology of Alzheimer’s disease (AD). We reveal here that reactive astrocytes control cell distancing in peri-plaque glial nets, which restricts microglial access to amyloid deposits. This process is governed by guidance receptor Plexin-B1 (PLXNB1), a network hub gene in individuals with late-onset AD that is upregulated in plaque-associated astrocytes. Plexin-B1 deletion in a mouse AD model led to reduced number of reactive astrocytes and microglia in peri-plaque glial nets, but higher coverage of plaques by glial processes, along with transcriptional changes signifying reduced neuroinflammation. Additionally, a reduced footprint of glial nets was associated with overall lower plaque burden, a shift toward dense-core-type plaques and reduced neuritic dystrophy. Altogether, our study demonstrates that Plexin-B1 regulates peri-plaque glial net activation in AD. Relaxing glial spacing by targeting guidance receptors may present an alternative strategy to increase plaque compaction and reduce neuroinflammation in AD.

Published
2024
Full Text
View/download PDF

4. Screening for modulators of autism spectrum disorder using induced human neurons

Author

Rao, Sumitha Rajendra, Kostic, Ana, Baillargeon, Pierre, Fernandez-Vega, Virneliz, de Anda, Mitzy Rios, Fletcher, Kelty, Shumate, Justin, Scampavia, Louis, Buxbaum, Joseph D, and Spicer, Timothy P.

Abstract

Autism Spectrum Disorder (ASD) is a heterogeneous neurodevelopmental disorder. There are no drugs to treat the core symptoms. De novomutations often play an important role in ASD and multiple high-risk loci have been identified in the last decade. These mutations range from copy number variants to small insertion/deletion and single nucleotide variants. Large-scale exome sequencing has identified over 100 risk genes that are associated with ASD. Both etiological heterogeneity and unavailability of human neurons remain major hurdles in understanding the pathophysiology of ASD and testing of new drug candidates. Hence, the most achievable and relevant model to screen for potential drugs is human neurons from inducible pluripotent stem cells (iPSCs), including those from individuals with genetic mutations. In this study, we tested stem cells from individuals carrying mutations in ADNP, FOXP1 or SHANK3. They were scaled and reprogrammed to glutamatergic neurons and assessed for the effects of their specific mutations on neurite outgrowth. High Content Analysis allowed us to observe phenotypic differences between ASD neurons compared to controls, in terms of neuron number, neurite number and neurite length per neuron. Further, neurons were derived from both patient derived and genetically modified iPSCs with DDX3X mutation which were tested against 5088 drug like compounds. We assessed individual compound effects on the induced neurons to determine if they elicited changes that would indicate neurite growth (neuroprotection) or, alternatively, reduce outgrowth and hence appear neurotoxic. This report includes all methods, phenotypic outcomes, and results for the largest ASD small molecule screening effort done to date.

Published
2022
Full Text
View/download PDF

5. Profitability of Supplemental Irrigation and Soil Dewatering for Potato Production in Atlantic Canada: Insights from Historical Yield and Weather Data

Author

Jiang, Yefang, Stetson, Tobin, Kostic, Ana, Anderson, Scott, and Ramsay, Matt

Abstract

Highly variable and unpredictable precipitation in humid regions makes water management important for consistent potato production. This study assessed the influence of supplemental irrigation (SI) and soil dewatering on potato productivity and profitability in Prince Edward Island, Canada. The average yields of Russet Burbank (RB), Shepody, Kennebec and Goldrush cultivars from 2000 to 2020 (excluding 2018) were conceptualized as the results of an un-replicated experiment with growing season (GS) precipitation representing water supply treatment. GS precipitation varied from 155 to 479 mm, with an average of 338 mm. Yield increased with increasing GS precipitation in the 155– 257 mm range (Rainfall Zone 1; 3/20 seasons), became relatively insensitive to GS precipitation in the 258–425 mm range (Rainfall Zone 2; 12/20 seasons), and decreased as GS precipitation increased from 426 to 479 mm (Rainfall Zone 3; 5/20 seasons). Yields responded to GS precipitation following second-order polynomial regressions, with GS precipitation explaining 69%, 65%, 29% and 50% of yield variation for RB, Shepody, Kennebec and Goldrush cultivars, respectively. These yield regression equations predict that SI using a center-pivot system would produce a positive profit in the first half of Rainfall Zone 1 regardless of field size and in the second half of Rainfall Zone 1 in fields over 40 ha. SI would not produce a positive profit in Rainfall Zone 2 regardless of field size because precipitation was high enough that additional water supply would not have resulted in sufficient yield gains to offset the cost of SI. Soil dewatering would be beneficial for optimal production in Rainfall Zone 3 in which precipitation was excessive. The annual variation in precipitation, unpredictability of SI requirements, and unprofitability in most seasons, present a significant financial barrier for the widespread implementation of SI. On the other hand, the gross income gained from increased yields by soil dewatering would fully cover the cost of tile drain installation after only two to three extremely wet seasons, making tile drainage a good investment for consistent production. This study demonstrates that historical rain-fed yield and weather data can be used to assess the economics of potato production with SI and soil dewatering, and provides important insights on potato water management in a humid temperate climate.

Published
2022
Full Text
View/download PDF

6. Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Author

Wright, Naomi Jane, Leather, Andrew J.M., Ade-Ajayi, Niyi, Sevdalis, Nick, Davies, Justine, Poenaru, Dan, Ameh, Emmanuel, Ademuyiwa, Adesoji, Lakhoo, Kokila, Smith, Emily Rose, Douiri, Abdel, Elstad, Maria, Sim, Marcus, Riboni, Cristiana, Martinez-Leo, Bruno, Akhbari, Melika, Tabiri, Stephen, Mitul, Ashrarur, Aziz, Dayang Anita Abdul, Fachin, Camila, Niyukuri, Alliance, Arshad, Muhammad, Ibrahim, Fowzia, Moitt, Natalie, Doheim, Mohamed Fahmy, Thompson, Hannah, Ubhi, Harmony, Williams, Isabelle, Hashim, Sophia, Philipo, Godfrey Sama, Herrera, Laura, Yunus, Aayenah, Vervoort, Dominique, Parker, Samuel, Benaskeur, Yousra-Imane, Alser, Osaid H., Adofo-Ansong, Nana, Alhamid, Ahmad, Salem, Hosni khairy, Saleh, Mahmoud, Elrais, Safa Abdal, Abukhalaf, Sadi, Shinondo, Patricia, Nour, Ibrahim, Aydin, Emrah, Vaitkiene, Agota, Naranjo, Kelly, Dube, Andile Maqhawe, Ngwenya, Sodumisa, Yacoub, Mina A., Kwasau, Henang, Hyman, Gabriella, Elghazaly, Shrouk Mahmoud, Al-Slaibi, Ibrahim, Hisham, Intisar, Franco, Helena, Arbab, Hana, Samad, Lubna, Soomro, Aqil, Chaudhry, Muhammad Amjad, Karim, Safina, Khattak, Muhammad Adnan Khan, Nah, Shireen Anne, Dimatatac, Doris Mae, Choo, Candy SC, Maistry, Niveshni, Mitul, Ashrarur Rahman, Hasan, Samiul, Karim, Sabbir, Yousuf, Hina, Qureshi, Taimur, Nour, Ibrahim Rabi, Al-Taher, Raed Nael, Sarhan, Osama Abdul Kareem, Garcia-Aparicio, Luis, Prat, Jordi, Blazquez-Gomez, Eva, Tarrado, Xavier, Iriondo, Martí, Bragagnini, Paolo, Rite, Segundo, Hagander, Lars, Svensson, Emma, Owusu, Sheila, Abdul-Mumin, Alhassan, Bagbio, Dominic, Ismavel, Vijay Anand, Miriam, Ann, T, Shajin, Anaya Dominguez, Marlene, Ivanov, Monica, Serban, Andreea Madalina, Derbew, Miliard, Elfiky, Mahmoud, Olivos Perez, Maricarmen, Abrunhosa Matias, Marcia, Arnaud, Alexis P, Negida, Ahmed, King, Sebastian, Fazli, Mohamad Rafi, Hamidi, Nadia, Touabti, Souhem, Chipalavela, Rossana Francisco, Lobos, Pablo, Jones, Brendan, Ljuhar, Damir, Singer, Georg, Hasan, Samiul, Cordonnier, Annelien, Jáuregui, Lorena, Zvizdic, Zlatan, Wong, Janice, St-Louis, Etienne, Shu, Qiang, Lui, Yang, Correa, Catalina, Pos, Lucie, Alcántara, Elvyn, Féliz, Erick, Zea-Salazar, Luis Enrique, Ali, Liza, Peycelon, Matthieu, Anatole, Nzanzu Kipata, Jallow, Cherno S., Lindert, Judith, Ghosh, Dhruv, Adhiwidjaja, Cathline Freya, Tabari, Ahmad Khaleghnejad, Lotfollahzadeh, Saran, Mussein, Haidar Mohammad, Vatta, Fabrizio, Pasqua, Noemi, Kihiko, David, Gohil, Hetal, Nour, Ibrahim R., Elhadi, Muhammed, Almada, Suad Ahmed, Verkauskas, Gilvydas, Risteski, Toni, Peñarrieta Daher, Alejandro, Outani, Oumaima, Hamill, James, Lawal, Taiwo, Mulu, Jack, Yapo, Benjamin, Saldaña, Lily, Espineda, Beda, Toczewski, Krystian, Tuyishime, Eugene, Ndayishimiye, Isaac, Raboe, Enaam, Hammond, Philip, Walker, Gregor, Djordjevic, Ivona, Chitnis, Milind, Son, Joonhyuk, Lee, Sanghoon, Hussien, Muaad, Malik, Sawazen, Ismail, Enas Musa, Boonthai, Ampaipan, Dahman, Nesrine Ben Hadj, Hall, Nigel, Castedo Camacho, Fabiola Ruth, Sobrero, Helena, Butler, Marilyn, Makhmud, Aliev, Novotny, Nathan, Hammouri, Ahmad G., Al-Rayyes, Maisara, Bvulani, Bruce, Muraveji, Qais, Murzaie, Muhammad Yousuf, Sherzad, Ajmal, Haidari, Sayed Aman, Monawar, Abdul Baqi, Samadi, Dr. Ahmad Zia, Thiessen, Jesh, Venant, Ntakarutimana, Hospital, Sonia Inamuco, Jérémie, Niyonkuru, Mbonicura, Jean Claude, Vianney, Butoyi Jean Marie, Tadesse, Amezene, Negash, Samuel, Roberts, Charles A., Jabang, John N., Bah, Abdoulie, Camamra, Kajali, Correa, Armandou, Sowe, Babucarr, Gai, A., Jaiteh, Musa, Raymond, Kwizera Jean, Mvukiyehe, Jean Paul, Itangishaka, Innocent, Kayibanda, Emmanuel, Manirambona, Emery, Lule, Joseph, Costas-Chavarri, Ainhoa, Shyaka Gashugi, Ian, Ndata, Albert, Gasana, Georges, Nezerwa, Yves Castar, Simeon, Turatsinze, Muragijimana, Jean De Dieu, Rashid, Sakina, Msuya, David, Elisante, Joseph, Solanki, Meghna, Manjira, Emmanuel, Lodhia, Jay, Jusabani, Mubashir, Tarmohamed, Murad, Koipapi, Sengua, Souhem, Touabti, Sara, Nabti, Sihem, Brahimi, Dania, Bouguermouh, Toufik, Iaiche Achour, Mounira, Baghdadi Nour el islam, Habiba, Alouani, Aragão, Liliana, Gonçalves, Victor, Lino Urquizo, Marcelo Mauricio, Varela, Maria Florencia, Mercado, Pedro, Horacio, Bonavia, Damiani, Andrea, Mac, Carlos, Putruele, Daniel, Liljesthrom, Karen, Bernaus, Marianela, Jauri, Cesar, Cripovich, Alejandrina, Bianchin, Ezequiel, Puig, Maria Gabriela, Andreussi, Lorna, Iracelay, Susana, Marcos, Dolores, Herrera, Carina, Palacios, Nelly, Avile, Romina, Serezo, Belen, Montoya, Debora, Cepeda, Rodrigo, Vaquila, Justo, Veronica, Sofficci, Pardo, Liliana, Valeria, Pelussi, Julio, Lapalma, Martin, Aranda Diego, Lucio, Palazzi, Gabriel, Comba, Marianella, Depetrini, Calderón Arancibia, José Alfredo, Huespe, Enrique, Losa, Gabriela Natalia, Arancibia Gutiérrez, Elsa, Scherl, Humberto, Gonzalez, Daniel Emilio, Baistrocchi, Valentina, Silva, Yanina, Galdeano, Marcelo, Medard, Pablo, Sueiras, Ines, Romero Manteola, Enrique, Defago, Victor Hugo, Mieres, Carlos, Alberto, Carlos, Cornelli, Fabio, Molina, Marcelo, Ravetta, Pablo, Patiño Gonzalez, Celeste Carolina, Dallegre, Maria Belen, Szklarz, Maria Tatiana, Leyba, Marcos Federico, Rivarola, Nahuel Ignacio, Charras, Maria Delia, Morales, Adriana, Caseb, Paloma, Toselli, Luzia, Millán, Carolina, Junes, Maria del Carmen, Di Siervi, Oscar, Gilardi, Jose, Simon, Soledad, Contreras, Carla Sofia, Rojas, Nair, Arnoletto, Lucia Beatriz, Blain, Otilia Eva, Bravo, Mauro Nicolas, Sanchez, Nancy, Herrera Pesara, Luciana Martina, Moreno, Maria Eugenia, Sferco, Carlos Ariel, Huq, Umama, Ferdousi, Tamanna, Al-Mamun, Abdullah, Sultana, Sadia, Mahmud, Refoyez, Mahmud, Khalid, Sayeed, Fatema, Svirsky, Alexander, Sempertegui, Denisse, Negrete, Amalia, Teran, Araceli, Sadagurschi, Mariana, Popovic, Nusret, Karavdic, Kenan, Milisic, Emir, Jonuzi, Asmir, Mesic, Amira, Terzic, Sabina, Dendusic, Nejra, Biber, Elna, Sehic, Anesa, Zvizdic, Nada, Letic, Emina, Saracevic, Adna, Hamidovic, Ajla, Selak, Nejra, Horozic, Dzan, Hukic, Lamija, Muhic, Amila, Vanis, Nedim, Sokolovic, Emir, Sabic, Adnan, Becker, Karin, Novochadlo Klüppel, Elis, dos Santos Dias, André Iván Bradley, Agulham, Miguel Angelo, Bischoff, Cristiano, Sabbatini, Stella, Fernandes de Souza, Rachel, Souza Machado, Ana Beatriz, Werneck Raposo, Juliana, da Silva Augusto, Maria Lucia, Martins, Bianca M.R., de Souza Santos Ferreira, Mariana, Fernandes de Oliveira, Darli, Silva dos Santos, Carla, Ribeiro de Fernández y Alcázar, Fernanda, Alves Dutra da Silva, Érika, Furtado, Mariana, Tamada, Horácio, Silva Ferreira dos Santos, Marília, Lopes de Almeida, Thayná, Oliveira de Andrade, Susy, Gurgel do Amaral, Antonio Cipriano, Sartori Giovanoni, Lais, de Deus Passos Leles, Kamila, Corrêa Costa, Eduardo, Feldens, Leticia, Ferraz Schopf, Luciano, Soares de Fraga, José Carlos, Colombo de Holanda, Felipe, Brolin Santis Isolan, Paola Maria, Loyola Ferreira, Julia, Bruxel, Carla Luisa, Lopes Teixeira Ferdinando, Danielle, Zottis Barcelos, Fabricio, Baseggio, Natalia, Knorr Brenner, Nicole, Trindade Deyl, Rafael, Dure, Carolina, Nunes Kist, Iuri, Bueno Mazzuca, Rafael, Bueno Motter, Sarah, Ramos, Yna, Suzana Trein, Cristine, Rezende Rosa, Bianca, de Assis Silva, Murilo, Menin, Flavio Augusto, Semensato Carloni, Isabela Cristina, Norberto da Silva, Juliana Antinarelli, Gomes, Adriano Luis, Girão Tauffer, Mariana, Bassan Gonçalves, Paulo César, Nogueira Marques, Geraldo Magela, Moriya, Eliane, Labonia, Carla, Carrasco, Ana Lucia, Furtado Meyer, Karine, Farion-Aguiar, Luiz, Amado, Fernando, Antunes, Amanda, Silva, Elisângela, Telles, Leila, Almeida, Giovana, Belmino Gadelha, Aluísio Augusto, de Azevedo Belesa, Flavia, Gonçalves da Cunha, Acimar, Jr, Souza Barros, Beatriz, Zanellato, Josiane Bernartt, Guimarães, Patricia, Silva, Karina Ilheu da, Ribas, Bianca, Reuter, Cristina, Casado, Francis Tanise, Correa Leite, Mila Torii, Testoni, Daniela, Guinsburg, Ruth, de Campos Vieira Abib, Simone, Khodor Cury, Edson, Dornellas do Nascimento, Suely, Almeida Aguiar, Arthur, Melo Gallindo, Rodrigo, Gonçalves Borges, Carolina, Liu, Yang, Duote, Cai, Wang, Jinhu, Gao, Zhigang, Liang, Liang, Luo, Wenjuan, Zhao, Xiaoxia, Chen, Rui, Wang, Peng, Han, Yijiang, Huang, Ting, Donglai, Hu, Xiaodong, Guo, Junjie, Chen, Zhu, Libin, Wu, Guowei, Bao, Xiaozhou, Li, Haijing, Lv, Junying, Li, Zhongrong, Yong, Feng, Gao, Zhou Chong, Bai, Qiang, Tang, Weibing, Xie, Hua, Motee, Jethishka, Zhu, Jianming, Wen, Gang, Ruan, Weiwei, Li, Shungen, Chen, Lulu, Huang, Shungen, Lv, Zhibao, Lu, Jinjing, Huang, Liuming, Yu, Mengnan, Dajia, Wang, Bai, Yu Zuo, Rincon, Luis Carlos, Mancera, Juliana, Alzate Gallego, Edgar, Torres-Canchala, Laura, Silva Beltrán, Nathalia, Osorio Fory, Ghordana, Castaño Avila, Daniela, Forero Ladino, Angelica Maria, Gomez, Juanita, Jaramillo, Martha, Morales, Otto, Sanchez, Beatriz, Tinoco Guzmán, Nestor Julien, Castañeda Espinosa, Sergio, Prieto Vargas, Osbaldo, Pardo, Lina Maria, Toral, Eliana, Cáceres Aucatoma, Freud, Hinostroza, Daniel, Valencia, Santiago, Salinas, Vicente, Landivar Cino, Enrique, Ponce Fajardo, Gabriela Yulissa, Astudillo, Miguel, Garcia, Virginia, Muñoz, Guillermo, Verduga, Leonardo, Verduga, Ivan, Murillo, Ericka, Bucaram, Elena, Guayelema, Marisol, Marmol, Monica, Sanchez, Janina, Vergara, Carolina, Mena, Adriana, Velaña, Junior, Salazar, Karla, Lara, Sandra, Chiriboga, Elena, Silva, Julian, Gad, Dalia, Samy, Doaa, Elsadek, Menan Ahmed, Mohammed, Hanan Mahmoud, Abouheba, Mohamed, Ali, Karim Osamy, Rashwan, Hayssam, Fawzy, Omar Moustafa, Kamel, Tarek mohamed, Nemer, Rawan, Hassan, Mohamed Abada, Falah, Eyad Hassan, Abdelhady, Dina Sobhy, Zain, Mostafa, Ibrahim, Eman Abouzeid Abouzeid, Elsiraffy, Omar Ossama, Aboelela, Ahmed, Farag, Eman mohamed, Oshiba, Ahmed Mohamed, Emam, Omar Sameh, Attia, Alaa Mobarak, Laymouna, Moustafa A., Ghorab, Islam Abdelmonem, Mohammed, Mansour Mkayed, Soliman, Nourhan Akram, Ghaly, Khaled Abd elrahman, Sadek, Kareem, Elsherbiny, Mohamed, Saleh, Amr, Sheir, Hesham, Wafa, Tamer, Elmenam, Mohamed Abd, Abdelmaksoud, Sherif, Reda, Ahmed, Mansour, Islam, Elzohiri, Mohamed, Waseem, Basma, Elewaily, Mohamed, El-Ghazaly, Mohammed, Elhattab, Ahmad, Shalaby, Amr, Elsaied, Adham, Adawy, Ahmad, Sadek, Mirna, Ahmed, Mahmoud Abdelfattah, Herdan, Mohamed Omar, Elassall, Gena Mohamed Hamed, Mohammed, Azhar Arabi, Takrouney, Mohammed Hamada, Essa, Tarek Mohamed, Mahmoud, Ahmed Mokhtar, Saad, Alshaimaa M., Fouly, Mariam Albatoul Nageh, Ibrahim, Mahmoud abdelshakour, Nageh, Mohammad, Saad, Mahmoud M., Badr, Helmy, Fouda, Mohamed Fayez, Nofal, Ahmed Hassan, Almohamady, Hisham, Arafa, Mohamed Ahmed, Amad, Mohamed, Mansour, Mohamed Awad, O'Connor, Jennifer, O'Connor, Zachary, Anatole, Nzanzu, Nkunzimana, Elysé, Machemedze, Solomon, Dieudonné, Lemfuka, Appeadu-Mensah, William, Anyomih, Theophilus Teddy Kojo, Alhassan, Priscilla, Abantanga, Francis A., Michael, Vishal, Mary Koshy, Roshine, Raj, Ankit, Kumar, Vijay, PT, Sundeep, Prabhu, P Santosh, Vosoughi, Armin, Al-Mayoof, Ali Farooq, Fadhle, Muhamed Jassim, Joda, Ali Egab, Algabri, Hayder Nadhim Obaid, Al-Taher, Raed Nael, Abdelhamid, Sultan S., Al-Momani, Hashem M., Amarin, Marzouq, Zaghlol, Louay Y., Alsaadi, Nijmeh Nasser, Qwaider, Yasmeen Z., Qutishat, Hibah, Aliwisat, Ahmad Hasan, Arabiat, Esraa, Bsisu, Isam, Murshidi, Raghad M., Jabaiti, Mohammad S., Bataineh, Ziad A., Abuhayyeh, Husam Aldean, Quran, Thekraiat M. Al, Za'nouneh, Faris J. Abu, Alebbini, Mohanad Mutasem, Qudah, Hamzah Abullah, Hussein, Omar Ghazi, Murad, Amir M.I., Amarin, Justin Z., Suradi, Haya H., Alzraikat, Sayel H., Omari, Rand Y., Matour, Bashar M., Al-Halbouni, Layana, Zurikat, Rajai O., Yanis, Ahmad H., Hussein, Sara Al, Shoubaki, Ali, Ghanem, Waleed H., David, Kuria, Chitiavi, Soita Wycliffe, Mose, Moraa, Mugo, Robert, Ndungu, James, Mwai, Timothy, Shahbal, Swaleh, Malik, Janan, Chauhan, Nirav, Syovata, Francisa, Ochieng, Kevin, Omendo Liyenzero, Polycarp, Hussain, Syeda Ra'ana, Mugambi, Stanley, Ochieng, Roseline, Elkhazmi, Ebtesam Othman Abdulsalam, Khaled, Ala, Albozidi, Aya, Enbaya, Manal Ben, Elgammudi, Mala, Soula, Enas, Khalel, Wegden ibrahim almabrouk, Elhajjaji, Yasmine Ali, Alwaggaa, Nouriyah Ali, Ghayth, Sumayyah, Zreeg, Dafer abdulhakim .S., Tantush, Sara Abobaker, Bibas, Fatma, Layas, Tesneem, Sharif, Randa Alamen M, Aljadidi, Wesal Omar F. Saied, Tarek, Ahmed, Ahmed, Hazem, Essamilghi, Kamila Almabrouk Mohammed, Alfoghi, Mabroka, Abuhlega, Ma'aly A., Arrmali, Saddam, Abduljawad, Fatima Mousa, Alosta, Hasan Mustafa, Abuajaila, Abdulsalam, Abdelmutalib, Fakereldeen, Bashir, Fatma, Almengar, Inas, Annajjar, Mohammad hasan, Deyab, Abdelaziz, Elzowawi, Fathi, Krayem, Yousef, Drah, Weam, Meftah, Asma, Mohammed, Abobaker, Arrmalli, Lina Ali, Aljaboo, Hajir, Elayeb, Abdallah, Altomi, Mohamed, Altaweel, Ahmed, Tumi, Mohamed, Bazozi, Hana Milad, Shaklawoon, Aisha, Alglaib, Mohammed Meftah, Elkaloush, Abdullahn Abdousalam, Trainba, Sara, Swessi, Hisham, Alnaeri, Ali, Shnishah, Aya Essam, Mustufa, Hamassat, Gargum, Sondas Ali, Tarniba, Sara Ali, Shalluf, Hawa Ahmed, Shokri, Hajer Ali, Sarkaz, Taher L., Tababa, Osama, Elhadi, Ahmed, Naunova, Vesna Cvetanovska, Jovcheski, Laze, Kamilovski, Marjan, Gavrilovska-Brzanov, Aleksandra, Latiff, Zarina Abdul, Pauzi, Siti Farhan Moh, Osman, Marjmin, Lim, Felicia, Bakar, Ainal Huda Abu, Zaman, Azrina SK, Ishak, Shareena, Teo, Rufinah, Qi, Dr. Tammy Teoh Han, Othman, Mohd Yusran Bin, Zahari, Dato' Dr Zakaria bin, Hassan, Zulfitri bin Md, Shan, Cheah Hui, Lechmiannandan, Abhirrami, Tamaddun, Hafatin Fairos bt, Adanan, Mohd Fitri Shukri bin Mohamed, Abdullah, Mohd Yusof bin, Junyi, Wang, Nor, Mohd. Tarmizi Mohd, Noor, Wan Ruzaimie, Hassan, Mohd Razin bin, Dalek, Noor Fa'izatul Rahil Ambok, Hashim, Hidayah Hayati binti, Zarwawi, Ahmad Zulhisyam bin, Vellusamy, V Muthualhagi M, Yuen, Quah Soong, Kannessan, Hemasutha a/p, Ramli, Najua binti, Bujarimin, Ahmad Shafiee bin, Anntinea, Jessmine, Dass, Anthony, Khalid, Hazlina Mohd., Hanifah, Nur Atiqah binti Mohd, Jyun, Keily Wong Yue, Razak, Rahilah binti Abd, Naim, Nur Atifah binti Mohd, Hamzah, Siti Nur Aien binti Hamid, Vidal, Cristian R. Zalles, Bracho Blanchet, Eduardo, Dávila Perez, Roberto, Fernandez Portilla, Emilio, Villegas Silva, Raúl, Ibarra, Daniel, Calderon Moore, Antonio, Carrasco-Ortega, Cesar, Noguez Castillo, Monica, Herappe Mellado, Dorihela, Yanowsky Reyes, Guillermo, Gonzalez Cortez, Luis Fernando, Santana Ortiz, Rafael, Orozco Perez, Jamie, Corona C.Rivera, Jorge Román, Cardenas Ruiz Velasco, Juan Jose, Quiles Corona, Moises, Peña Padilla, Christian, Bobadilla Morales, Lucina, Corona Rivera, Alfredo, Rios Flores, Izabel Maryalexandra, Aranda Sánchez, Cristian Irela, Ambriz-González, Gabriela, Martínez Hernández Magro, Nestor, León Frutos, Francisco Javier, Cárdenas Barón, José de Jesús, González Ojeda, Alejandro, Yarza Fernández, Jessica, Porras, Juan Domingo, Aguirre-Lopez, Pastor, Sánchez Paredes, Vicente, Montalvo Marin, Arturo, Diaz Gomez, Jose Manuel, Caamal, Lorenzo Juvencio, Bulnes Mendizabal, David, Sanchez Valladares, Pablo, Garcia Martinez, Humberto, Adesanya, Opeoluwa, Olanrewaju, Moses, Adegboyega, Rilwan, Abdulraheem, Nurudeen, Aremo, Anuoluwapo, Dedeke, Florence, Chukwuemeka, Anyanwu Lofty-John, Mohammad, Mohammad Aminu, Lawalbarau, Abdullahi, Collins, Nwokoro, Ibukunolu, Ogundele, Shonubi, Amo, Ladipo-Ajayi, Oluwaseun, Elebute, Olumide Abiodun, Seyi-Olajide, Justina, Alakaloko, Felix, Ihediwa, George, Olayade, Kayode, Bode, Christopher, Ogundoyin, Olakayode, Olulana, Dare I., Egbuchulem, Ifeanyichukwu Kelvin, Kumolalo, Felix O., Ulasi, Ikechukwu, Ezomike, Uchechukwu Obiora, Ekenze, Sebastian Okwuchukwu, Nwankwo, Elochukwu Perpetua, Nwangwu, Emmanuel Ifeanyi, Chukwu, Isaac, Amah, Christopher Chim, Obianyo, Nene Elsie, Williams, Omolara, Osuoji, Roland Iheanyichukwu, Faboya, Omolara Moronkeji, Ajai, Olalekan Temitope, Abdulsalam, Moruf Adekunle, Agboola, Titiloye Hannah, Temilade, Bolarinwa Bolanle, Osazuwa, Maryrose, Salawu, Morayo Monsurat, Ejinkeonye, Eze Chukwuemeka, Yola, Mariya Mukhtar, Mairami, Amsa B., Otuneye, Adekunle T., Igoche, Matthias, Tanimola, Adebayo Gbenga, Ajao, Emmanuel Akinlabi, Agelebe, Efeturi, Olori, Samson, Mshelbwala, Philip Mari, Osagie, Olabisi, Oyinloye, Adewale, Abubakar, Auwal M, Oyebanji, Lateef, Shehu, Ibrahim, Cletus, Cyril, Bamanga, Ahmed, Suleiman, Faruk, Adamu, Sani, C.Nwosu, David, S.Alkali, Yahya, Jalo, Iliya, Rasaki, Aliu, T.Sambo, Yusuf, A.Mohammed, Kalakwa, M.Ballah, Abubakar, Modekwe, Victor, Ekwunife, Okechukwu Hyginus, Ezidiegwu, Ugochukwu S, Osuigwe, Andrew N, Ugwu, Jideofor O, Ugwunne, Chuka A, Akhter, Nadeem, Gondal, Mudassir Fayaz, Raza, Rafee, Chaudary, Ali Raza, Ali, Hassan, Nisar, Muhammad Umar, Jamal, Muhammad Umer, Pandit, Ghuri Shankar, Mumtaz, Uzma, Amjad, Muhammad Bin, Talat, Nabila, Rehman, Wajeeh ur, Saleem, Muhammad, Mirza, Muhammad Bilal, Hashim, Imran, Haider, Naveed, Hameed, Soban, Saleem, Ayesha, Dogar, Sohail, Sharif, Muhammad, Bashir, Muhammad Kashif, Naumeri, Fatima, Rani, Zarqa, Baniowda, Muath A.M., Ba'baa', Basheer, Hassan, Majd Yousef Mohammed, Darwish, Ammar, Sehwiel, Abrar Shaheen, Shehada, Mohammed, Balousha, Abrar ghassan, Ajrami, Yara, Alzamari, Ainaa Ata Mohammad, Yaghi, Bashar, Al-saleem, Hasan Subhi Hasan Abu, Farha, Mervat Sufian Abu, Abdelhafez, Mohammad Omar Mohammad, Anaya, Firas, Qadomi, Asef belal, Odi, Abd Al-Naser Bany, Assi, Muath Abdelrahem Fuad, Sharabati, Fadwa, Abueideh, Ahmad, Beshtawi, Doha mustafa saleh, Arafat, Hasan, Khatatba, Lara Zahi Adel, Abatli, Safa' Jamal, Al-Tammam, Hiba, Jaber, Dania, Kayed, Yara Imad Omar, Abumunshar, Ali Abdelhay, Misk, Rami Anwar, Alzeer, Asmahan Mohammad Suliman, Sharabati, Mutassem, Ghazzawi, Ihsan, Darras, Osama Majed, M.Qabaja, Mahmoud, Hajajreh, Ma'alem sameer, Samarah, Yasmeen Ahmad, Yaghi, Dua Hasan, Qunaibi, Moradallah Asad Fahmi, Mayaleh, Abdelrazzaq Abu, Joubeh, Sharehan, Ebeido, Annan, Adawi, Samer, Adawi, Ihda, Alqor, Mohammad Omar Ibrahim, Arar, Ahmad Samih, Awad, Hadeel, Abu-Nejmah, Fawzi, Shabana, Osaid Shaher, Alqarajeh, Firas, Alzughayyar, Tareq Z., Madieh, Jomana, Sbaih, Mahmoud Fuad, Alkareem, Raghad mohammad abdu, Lahlooh, Raghad abdullateef, Halabi, Yasmeen Adly, Baker, Wisam, Almusleh, Tasneem Fathi Hasan, Tahyneh, Abdulraheem Adnan Abdulraheem, Atatri, Yazid yousef mahmoud, Jamie, Najlaa Abu, Massry, Nasrallah Ashraf Al, Lubbad, Walaa, A.Nemer, Ayoub, Alser, Mohammed, Salha, Aya Azmi Shehda, Alnahhal, Khaled, Elmzyyen, Aya Mahmoud, Ghabayen, Amir Talat Sheda, Alamrain, Abdulwhhab Ayman Abu, Al-Shwaikh, Samar H., Elshaer, Omar Adly, Shaheen, Nureddin, Fares, Jehad, Dalloul, Hisham, Qawwash, Anas, Jayyab, Mustafa abu, Ashour, Dina Ayman, Shaheen, Ahmad Ashraf, Naim, Samy Rafat Ramadan, Shiha, Eman Abu, Dammagh, Nagham Mohammed Al, Almadhoun, Walaa, Al-Salhi, Ashraf Ayman, Hammato, Abdalkarim Yhya, Salim, Jamal Mohammed, Hasanain, Doaa Khalil, Alwadia, Soha Marwan Salem, Nassar, Ismail, Al-Attar, Hala M., Alshaikhkhalil, Haya Abdulnasser Ali, Jamie, Yasmin Mohammed Khalil Abu, Ashour, Yara shareef, Alijla, Sharif S., Tallaa, Mohamed Anwer El, Abuattaya, Adham Ashraf, Wishah, Bisan D.M., ALDIRAWI, MOHAMMED A.M., Darwish, Ahmed S, Alzerei, Sulaiman T., Wishah, Nidal, Alijla, Sharif, Garcia, Isidora, Diaz Echegaray, Marlene, Cañapataña Sahuanay, Veronica Raquel, Trigoso Mori, Fernando, Alvarado Zelada, Jackelyne, Salinas Barreto, Juan Jose, Rivera Altamirano, Porfirio, Torres Miranda, Cesar, Anicama Elias, Rocio, Rivera Alvarez, Julio, Vasquez Matos, Juan Pedro, Ayque Rosas, Fernando, Ledesma Peraza, Jesmarina, Gutarra Palomino, Andrea, Vega Centen, Stephany, Casquero, Victor, Ortiz Argomedo, María Rosa, Lapouble, Francisco, Llap Unchón, Genaro, Delgado Malaga, Florangel Patricia, Ortega Sotelo, Luis, Gamboa Kcomt, Segundo, Villalba Villalba, Araceli, Mendoza Leon, Nancy Rossana, Cardenas Alva, Loreley Raquel, Loo Neyra, Maria Susana, Alanguia Chipana, Cathy Lee, Torres Picón, Cintya Maria de Jesus, Huaytalla Quiroz, Natalia, Dominguez, Danny, Segura Calle, Carlos, Arauco, Jenny, Ormeño Calderón, Luis, Ghilardi Silva, Ximena, Fernandez Wilson, Miriam Daniela, Gutierrez Maldonado, Joan Elizabeth, Diaz Leon, Cesar, Berrocal Anaya, Waldo, Chavez Galvez, Patricia, Aguilar Gargurevich, Prince Pamela, Diaz Castañeda, Flor de Maria, Guisse, Carmen, Ramos Paredes, Erika, Apaza Leon, Jose Luis, Aguilar Aguilar, Faye, Ramirez De La Cruz, Raul, Flores Carbajal, Lenny, Mendoza Chiroque, Carlos, Sulca Cruzado, Gladys Johana, Tovar Gutierrez, Natalia, Sotelo Sanchez, Jennifer, Paz Soldan, Carolina, Hernández Córdova, Karina, Delgado Quinteros, Edgar Fernando, Brito Quevedo, Luz Mery, Mendoza Oviedo, Juan Jose, Samanez Obeso, Angel, Paredes Espinoza, Patricia, de Guzman, Johann, Yu, Raisa, Cosoreanu, Vlad, Ionescu, Sebastian, Mironescu, Aurel, Vida, Lucian, Papa, Adrian, Verdeata, Roxana, Gavrila, Bogdan, Muntean, Liviu, Lukac, Marija, Stojanovic, Miona, Toplicic, Djordje, Slavkovic, Milan, Slavkovi, Andjelka, Zivanovic, Dragoljub, Kostic, Ana, Raicevic, Maja, Nkuliza, Delphine, Sidler, Daniel, Vos, Corné de, Merwe, Elmarie vd, Tasker, David, Khamag, Omar, Rengura, Cecilia, Siyotula, Thozama, Jooma, Uzair, Delft, Dirk von, Arnold, Marion, Mangray, Hansraj, Harilal, Shamaman, Madziba, Sanele, Wijekoon, Naveen, Gamage, Tharanga, Bright, Benedict Paul, Abdulrahman, Alaa, Mohammed, Ola Ahmed Abdulmjeed, Salah, Mohammed, Ajwa, Ahmad Elian Abu, Morjan, Mohammed, Batal, Mohammad Mohannad, Faks, Vivian, Mouti, Mohamad Bassel, Assi, Ahmadfateh, Al-Mouakeh, Ahmad, Tarabishi, Ahmad Sankari, Aljarad, Ziad, Alhamid, Aos, Khorana, Jiraporn, Poocharoen, Wannisa, Liukitithara, Sirima, Sriniworn, Anan, Nuntasunti, Wasun, Ngerncham, Monawat, Phannua, Ratiyaporn, Thaiwatcharamas, Kanokrat, Tanming, Patchareeporn, Sahnoun, Lassaad, Kchiche, Nahla, Abdelmoumen, Roua, Eroğlu, Egemen, Ozen, Mehmet Ali, Cömert, Hatice Sonay Yalçın, İmamoğlu, Mustafa, Sarıhan, Haluk, Kader, Şebnem, Mutlu, Mehmet, Aslan, Yakup, Beşir, Ahmet, Geze, Şükran, Çekiç, Bahanur, Yalcinkaya, Ali, Sönmez, Kaan, Karabulut, Ramazan, Türkyılmaz, Zafer, Şeref, Kıvanç, Altın, Merve, Aykut, Merve, Akan, M.Eren, Erdem, Melisa, Ergenekon, Ebru, Türkyılmaz, Canan, Keleş, Elif, Canözer, Ali, Yeniay, Aslı Öztürk, Eren, Elif, Cesur, İlknur Banlı, Özçelik, Zerrin, Kurt, Gökmen, Mert, Mustafa Kurthan, Kaya, Hatice, Çelik, Müge, Karakus, Suleyman Cuneyt, Erturk, Nazile, Suzen, Alev, Hakan, Nilay, Akova, Fatih, Pasaoglu, Mehmet, Eshkabilov, Shukurali, Yuldashev, Rustam Z., Abdunomonovich, Dekhkonboev Avazjon, Muslimovich, Aliev Makhmudjan, Patel, Azad, Kapihya, Chisengo, Ensar, Nicholas, Nataraja, Ramesh M, Sivasubramaniam, Mithila, Jones, Matthew, Teague, Warwick, Tanny, Sharman Tan, Thomas, Gordon, Roberts, Kiera, Venkatraman, Soundappan Sannappa, Till, Holger, Pigeolet, Manon, Dassonville, Martine, Shikha, Anas, Win, Win Sabai Phyu, Ahmad, Zahidah Adlynee Haji, Meloche-Dumas, Léamarie, Caouette-Laberge, Louise, St-Vil, Dickens, Aspirot, Ann, Piché, Nelson, Joharifard, Shahrzad, Safa, Nadia, Laberge, Jean-Martin, Emil, Sherif, Puligandla, Pramod, Shaw, Kenneth, Wissanji, Hussein, Duggan, Eileen, Guadagno, Elena, Puentes, Maria Consuelo, Leal, Paola Osses, Mendez Benavente, Carolina, Rygl, Michal, Trojanová, Barbora, Berková, Klára, Racková, Tereza, Planka, Ladislav, Škvařil, Jan, Štichhauer, Radek, Sabti, Shahad, Macdonald, Alex, Bouhadiba, Nordeen, Kufeji, Dorothy, Pardy, Caroline, Mccluney, Simon, Keshtgar, Alireza, Roberts, Rebecca, Rhodes, Hannah, Burns, Kate, Garrett-Cox, Robin, Ford, Kat, Cornwall, Hannah, Ravi, Krithi, Arthur, Felicity, Losty, Paul, Lander, Tony, Jester, Ingo, Arul, Suren, Gee, Oliver, Soccorso, Giampiero, Singh, Michael, Pachl, Max, Martin, Benjamin, Alzubair, Afnan, Kelay, Arun, Sutcliffe, Jonathan, Middleton, Thomas, Thomas, Amy Hughes, Kurian, Merina, Cameron, Fraser, Sivaraj, Jayaram, Thomas, Mark C, Rex, Dean, Jones, Ceri, Bradshaw, Kate, Bonnard, Arnaud, Delforge, Xavier, Duchesne, Camille, Gall, Caroline Le, Defert, Coralie, Laraqui Hossini, Samia, Guerin, Florent, Hery, Géraldine, Fouquet-Languillat, Virginie, Kohaut, Jules, Broch, Aline, Blanc, Thomas, Harper, Luke, Delefortrie, Thomas, Ballouhey, Quentin, Fourcade, Laurent, Grosos, Céline, Parmentier, Benoit, Levard, Guillaume, Grella, Maria Giovanna, Renaux Petel, Mariette, Grynberg, Lucie, Abbo, Olivier, Mouttalib, Sofia, Juricic, Mélodie, Scalabre, Aurelien, Haraux, Elodie, Rissmann, Anke, Krause, Hardy, Goebel, Peter, Patzer, Ludwig, Rolle, Udo, Schmedding, Andrea, Antunez-Mora, Alexandra, Tillig, Bernd, Bismarck, Sylvester von, Barbosa, Patricia Reis, Knorr, Christian, Stark, Domitille, Brunero, Marco, Avolio, Luigi, Manni, Francesco, Molinelli, Matilde, Guazzotti, Marinella, Raffaele, Alessandro, Romano, Piero Giovanni, Cavaiuolo, Silvia, Parigi, Gian Battista, Juhasz, Laszlo, Rieth, Anna, Strumila, Arunas, Dagilytė, Rūta, Liubsys, Arunas, Gurskas, Pranas, Malcius, Dalius, Mikneviciute, Agne, Vinskaite, Asta, Barauskas, Vidmantas, Vierboom, Liam, Hall, Timothy, Beasley, Spencer, Goddard, Lucy, Stringer, Mark, Weeratunga, Naveen, Adams, Stephen, Cama, Jitoko, Wong, Marilyn, Jayaratnam, Sridharan, Kukkady, Askar, Samarakkody, Udaya, Gerus, Sylwester, Patkowski, Dariusz, Wolny, Agnieszka, Koszutski, Tomasz, Tobor, Szymon, Osowicka, Marta, Czauderna, Piotr, Wyrzykowski, Dariusz, Garnier, Hanna, Anzelewicz, Stefan, Marta, Osowicka, Knurowska, Agata, Weiszewsk, Alicja, Grabowski, Andrzej, Korlacki, Wojciech, Pasierbek, Michal, Wolak, Przemyslaw, Piotrowska, Aneta, Roszkiewicz, Anna, Kalicińsk, Piotr, Trypens, Agata, Kowalewsk, Grzegorz, Sigalet, David, Alsaied, Amer, Ali, Mansour, Alsaggaf, Ameen, Ghallab, Alaa, Owiwi, Yazeed, Zeinelabdeen, Ali, Fayez, Mohamed, Atta, Ahmed, Zidan, Mazen, Radwan, Asaad saleh, Shalaby, Hanin, Abdelbaqi, Reem, Alattas, Khalid, Kano, Yar, Sindi, Omar, Alshehri, Abdullah, Altokhais, Tariq, Alturki, Fahad, Almosaibli, Mohammad, Krisanova, Dasha, Abbas, Wisam, Yang, Hee-Beom, Kim, Hyun-Young, Youn, Joong Kee, Chung, Jae Hee, Cho, Seok Hyeon, Hwang, In ji, Lee, Ju yeon, Song, Eung song, Arboleda, Jenny, Ruiz de Temiño Bravo, Mercedes, Siles Hinojosa, Alexander, García, Miriam, Casal Beloy, Isabel, Oliu San Miguel, Detlef, Molina Vazquez, Maria Elena, Alonso, Verónica, Sanchez, Alberto, Gomez, Oscar, Carrillo, Isabel, Wester, Tomas, Mesas Burgos, Carmen, Hagander, Lars, Salö, Martin, Omling, Erik, Rudolfson, Niclas, Granéli, Christina, Arnadóttir, Helena, Grottling, Emma, Abrahamsson, Kate, Gatzinsky, Vladimir, Dellenmark Blom, Michaela, Borbonet, Daniel, Puglia, Paul, Jimenez Morejon, Vinicio, Acuna, Gaston, Moraes, Mario, Chan, Jonathan, Brahmamdam, Pavan, Tom, Alan, Sherer, Karen, Gonzales, Brandy, Cunningham, Aaron, Krishnaswami, Sanjay, Baertschiger, Reto, Leech, Mary, Williams, Regan, Camp, Lauren, Gosain, Ankush, Mora, Maria, Lyttle, Bailey D., Chang, Jeremy, McColl Makepeace, Lydia, Fowler, Kathryn L, Mansfield, Sara, Hodgman, Erica, Amaechi, Chukwubinyelum, Beres, Alana, Pernik, Mark N., Dosselman, Luke J., Almasri, Murad, Jain, Sunil, Modi, Varun, Fernandez Ferrer, Marianelly, Coon, John, Gonzalez, Joann, Honhar, Medhavi, Ruzgar, Nensi, Coghill, Griffin, Ullrich, Sarah, Cheung, Maija, Løfberg, Katrine, Greenberg, Jodie, Davenport, Kate, Gadepalli, Samir, Fox, Sarah, Johnson, Stephanie, Pilkington, Mercedes, Hamilton, April, Lin, Nicole, Sola, Juan, Yao, Yang, Davis, Jenna Kylene, Langer, Monica, Vacek, Jonathan, Abdullah, Fizan, Khlevner, Julie, Middlesworth, William, Levitt, Marc, Ahmad, Hira, Siddiqui, Sabina M, Bowder, Alex, Derks, Terry, Amoabin, Afua Amoabin, Pinar, Brooke, Owusu-Sekyere, Frank, Saousen, Benmanseur, Naidoo, Rasika, Karamustafic, Azra, Oliveira, Danielle Paula de, Motter, Sarah Bueno, Andrade, Jerhy, Šafus, Antonín, Langley, Jason, Wilke, Alexandra, Deya, Corazone, Murtadi, Habib Mansour, Berzanskis, Mindaugas, Calistus, Nwachukwu, Ajiboye, Olalekan S., Felix, Michael, Olabisi, Osagie O, Erçin, Seçil, Muradi, Teymursha, Burks, Stephen S., Lerma, Sergio, Jacobson, Jillian, Calancea, Calin, Valerio-Vazquez, Rafael, Sikwete, Guigui, Sekyere, Owusu, Mbonisweni, Akhona, Syed, Shahnoor, Hyeon, Cho Seok, Pajouhandeh, Fatemeh, and Kunfah, Sheba Mary Pognaa

Abstract

Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality.

Published
2021
Full Text
View/download PDF

7. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Author

Abramson, Jeremy S, Palomba, M Lia, Gordon, Leo I, Lunning, Matthew A, Wang, Michael, Arnason, Jon, Mehta, Amitkumar, Purev, Enkhtsetseg, Maloney, David G, Andreadis, Charalambos, Sehgal, Alison, Solomon, Scott R, Ghosh, Nilanjan, Albertson, Tina M, Garcia, Jacob, Kostic, Ana, Mallaney, Mary, Ogasawara, Ken, Newhall, Kathryn, Kim, Yeonhee, Li, Daniel, and Siddiqi, Tanya

Abstract

Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety of liso-cel in patients with relapsed or refractory large B-cell lymphomas.

Published
2020
Full Text
View/download PDF

8. Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001

Author

Palomba, M. Lia, Siddiqi, Tanya, Gordon, Leo I., Kamdar, Manali, Lunning, Matthew, Hirayama, Alexandre V, Abramson, Jeremy S., Arnason, Jon, Ghosh, Nilanjan, Mehta, Amitkumar, Andreadis, Charalambos, Solomon, Scott R., Kostic, Ana, Singh, Ashvin, Espinola, Ricardo, Peng, Lily, Ogasawara, Ken, Chattin, Amy, and Wang, Michael

Abstract

In R/R MCL, several high-risk features are associated with a worse prognosis including TP53mutation, high Ki-67 proliferation index, blastoid morphology, and secondary CNS involvement. We report outcomes from prespecified subgroup analyses based on high-risk features from the MCL cohort of TRANSCEND NHL 001 (NCT02631044) of liso-cel in pts with R/R MCL.

Published
2024
Full Text
View/download PDF

9. Nex-T TMCluster of Differentiation 19 (CD19) Chimeric Antigen Receptor (CAR) T-Cell Therapy BMS-986353 (CC-97540): Comparative Analysis of Baseline Patient Data from Trials in Systemic Lupus Erythematosus (SLE) and Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Related to Manufacturability and Potential Safety

Author

Mueller, Fabian, Rytlewski, Julie, Wu, Chun, Hu, Sarah, Koegel, Ashley, Delev, Nikolay, Kostic, Ana, Shah, Vaishali, Wegman, Thomas, and Schett, Georg

Abstract

Introduction: CAR T-cell therapy is currently being evaluated in non-oncologic autoimmune diseases (Mougiakakos D et al. N Engl J Med2021; Müller F et al. Lancet2023). In a cohort of patients (pts) with SLE, CD19 CAR T-cell therapy resulted in B-cell depletion and treatment-free, durable remission per Definitions of Remission In SLE (DORIS), suggesting that CD19 CAR T therapy may be feasible, well-tolerated, and effective for patients with SLE (Mackensen A et al. Nat Med2022). Baseline traits associated with greater manufacturing success and lower toxicity profiles for CAR T have been identified in hematologic oncology (Mashadi-Hossein A et al. J Clin Oncol2023; Rytlewski J et al. J Clin Oncol2022) including age, bone marrow function, inflammatory state, and tumor burden. Here, we compared baseline traits in pts with active SLE versus R/R LBCL to predict the potential manufacturing success and toxicity profile for the ongoing phase 1 study to evaluate the investigational NEX-T TMCAR T-cell product BMS-986353 (CC-97540) in pts with severe, refractory SLE (NCT05869955).

Published
2023
Full Text
View/download PDF

10. Long-term Follow-up from Qualitative Interviews of Patients with Relapsed or Refractory Large B-Cell Lymphoma on Their Treatment Experience While Enrolled in a Lisocabtagene Maraleucel Study

Author

Barba, Pere, Lanar, Sally, Liu, Fei Fei, Eliason, Laurie, Askew, Kshawna, Devlen, Jennifer, Furustrand, Ulrika, and Kostic, Ana

Abstract

Background: Patients(pts) with R/R large B-cell lymphoma (LBCL) have rapid and durable responses when treated with lisocabtagene maraleucel (liso-cel), a CD19-directed CAR T cell therapy. The safety profile is manageable with low rates of grade ≥ 3 cytokine release syndrome, neurological events, and infections and no new safety signals after long-term follow-up (Abramson JS, et al. Blood2021). Qualitative pt interviews can generate meaningful data to gain deeper understanding of the treatment (tx) experience and benefit from the pt perspective, help interpret pt-reported outcome (PRO) scores, and help identify what is most important to pts. Previous qualitative pt interviews within the context of a clinical trial showed positive pt experience in the first 3 months after liso-cel infusion (Siddiqi T, et al. Blood2021). This analysis assessed pt perceptions of liso-cel tx 6‒24 months after infusion.

Published
2023
Full Text
View/download PDF

11. Patient-Reported Outcomes from the MCL Cohort of the Phase 1, Seamless Design TRANSCEND NHL 001 Study of Lisocabtagene Maraleucel in Patients with R/R B-Cell NHL

Author

Wang, Michael L., Gordon, Leo I., Hirayama, Alexandre V, Lunning, Matthew A, Shi, Ling, Guo, Shien, Kostic, Ana, Eliason, Laurie, Kumar, Jinender, and Palomba, Maria Lia

Abstract

Background: MCL is an aggressive form of NHL. Despite high initial response rates to currently available frontline therapies for newly diagnosed MCL, patients will inevitably experience relapse. Survival outcomes are poor for patients with R/R MCL. Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, 4-1BB CAR T cell product administered at equal target doses of CD8 +and CD4 +CAR +T cells. In the primary analysis of the MCL cohort from the phase 1, seamless design TRANSCEND NHL 001 study (NCT02631044), liso-cel treatment resulted in a rapid, high ORR and high rate of durable CR with low incidences of grade ≥ 3 cytokine release syndrome, neurological events, and infections in heavily pretreated patients with high-risk, aggressive R/R MCL (Wang M, et al. Hematol Oncol2023). Here, we present patient-reported outcomes (PRO) results from the MCL cohort of TRANSCEND NHL 001.

Published
2023
Full Text
View/download PDF

12. Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study

Author

Palomba, Maria Lia, Siddiqi, Tanya, Gordon, Leo I., Kamdar, Manali, Lunning, Matthew A, Hirayama, Alexandre V, Abramson, Jeremy S., Arnason, Jon E., Ghosh, Nilanjan, Mehta, Amitkumar, Andreadis, Charalambos, Solomon, Scott R., Kostic, Ana, Singh, Ashvin, Espinola, Ricardo, Peng, Lily, Ogasawara, Ken, Chattin, Amy, and Wang, Michael L.

Abstract

Background: Pts with R/R MCL after ≥ 2 prior lines of therapy, including a Bruton tyrosine kinase inhibitor (BTKi), have poor prognosis. Among pts with R/R MCL, several high-risk disease features are associated with a worse prognosis, including TP53mutation, high proliferation index (Ki-67 ≥ 30%), blastoid morphology, and secondary CNS involvement. Liso-cel is an autologous, CD19-directed, 4-1BB CAR T cell product administered at equal target doses of CD8 +and CD4 +CAR +T cells. In the primary analysis of the MCL cohort from the phase 1, seamless design TRANSCEND NHL 001 study (NCT02631044), liso-cel treatment resulted in a rapid, high rate of durable CRs with a manageable safety profile in pts with heavily pretreated R/R MCL. Here we report the outcomes in pts with R/R MCL from prespecified subgroup analyses based on high-risk disease features.

Published
2023
Full Text
View/download PDF

14. Two-Year (yr) Follow-up (FU) of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Author

Abramson, Jeremy S., Palomba, M. Lia, Gordon, Leo I., Lunning, Matthew, Wang, Michael, Arnason, Jon E., Purev, Enkhtsetseg, Maloney, David G., Andreadis, Charalambos, Sehgal, Alison R., Solomon, Scott R., Ghosh, Nilanjan, Kostic, Ana, Kim, Yeonhee, Ogasawara, Ken, Dehner, Christine, and Siddiqi, Tanya

Published
2022
Full Text
View/download PDF

16. Fibronectin Rigidity Response through Fyn and p130Cas Recruitment to the Leading Edge

Author

Kostic, Ana and Sheetz, Michael P.

Abstract

Cell motility on extracellular matrices critically depends on matrix rigidity, which affects cell adhesion and formation of focal contacts. Receptor-like protein tyrosine phosphatase alpha (RPTPα) and the αvβ3integrin form a rigidity-responsive complex at the leading edge. Here we show that the rigidity response through increased spreading and growth correlates with leading edge recruitment of Fyn, but not endogenous c-Src. Recruitment of Fyn requires the palmitoylation site near the N-terminus and addition of that site to c-Src enables it to support a rigidity response. In all cases, the rigidity response correlates with the recruitment of the Src family kinase to early adhesions. The stretch-activated substrate of Fyn and c-Src, p130Cas, is also required for a rigidity response and it is phosphorylated at the leading edge in a Fyn-dependent process. A possible mechanism for the fibronectin rigidity response involves force-dependent Fyn phosphorylation of p130Cas with rigidity-dependent displacement. With the greater displacement of Fyn from p130Cas on softer surfaces, there will be less phosphorylation. These studies emphasize the importance of force and nanometer-level movements in cell growth and function.

Published
2006
Full Text
View/download PDF

17. Characteristics of Post-Infusion Chimeric Antigen Receptor (CAR) T Cells and Endogenous T Cells Associated with Early and Long-Term Response in Lisocabtagene Maraleucel (liso-cel)-Treated Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Author

Thorpe, Jerill, Jiang, Yue, Rytlewski, Julie A, Kostic, Ana, Kim, Yeonhee, and Peiser, Leanne

Abstract

Background:Liso-cel is an autologous, CD19-directed, defined composition, 4-1BB CAR T cell product administered at equal target doses of CD8 +and CD4 +CAR +T cells. In the pivotal TRANSCEND NHL 001 study (NCT02631044) in patients (pts) with R/R LBCL after ≥ 2 prior lines of therapy, liso-cel demonstrated significant clinical activity with an objective response rate of 73%, complete response (CR) rate of 53%, and median duration of response (DOR) not reached at 12 months' median DOR follow-up, and a low incidence of severe cytokine release syndrome (2%) and neurological events (10%; Abramson et al. Lancet2020;396:839-852). While CAR T cells have shown remarkable efficacy in treating LBCL, with a well-understood mechanism of direct CAR T cell tumor killing, the contribution of the endogenous immune system in this response is currently unclear. Previously, histologic and gene expression analysis of pre- and posttreatment tumor biopsies from pts who received liso-cel in TRANSCEND NHL 001 showed a relationship between tumor-infiltrating CAR-negative (endogenous) T cells and early and durable response [Reiss et al. Blood2019;134(suppl 1):202].

Published
2021
Full Text
View/download PDF

18. Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Author

Abramson, Jeremy S., Palomba, M. Lia, Gordon, Leo I., Lunning, Matthew A., Wang, Michael, Arnason, Jon E., Purev, Enkhtsetseg, Maloney, David G., Andreadis, Charalambos, Sehgal, Alison R., Solomon, Scott R., Ghosh, Nilanjan, Kostic, Ana, Kim, Yeonhee, Ogasawara, Ken, Dehner, Christine, and Siddiqi, Tanya

Abstract

Background:LBCLs are prevalent and aggressive subtypes of NHL, with limited treatment options and historically poor outcomes in the third- or later-line setting. Liso-cel is an autologous, CD19-directed, defined composition, 4-1BB CAR T cell product administered at equal target doses of CD8 +and CD4 +CAR +T cells. TRANSCEND NHL 001 (NCT02631044) is a seamless design, pivotal, phase 1 study evaluating liso-cel in patients (pts) with R/R LBCLs (Abramson et al. Lancet2020). We present 2-year follow-up data from the LBCL cohort.

Published
2021
Full Text
View/download PDF

19. Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Author

Abramson, Jeremy S., Palomba, Maria Lia, Gordon, Leo I., Lunning, Matthew A., Wang, Michael L., Arnason, Jon E., Mehta, Amitkumar, Purev, Enkhtsetseg, Maloney, David G., Andreadis, Charalambos, Sehgal, Alison R., Solomon, Scott R., Ghosh, Nilanjan, Albertson, Tina, Garcia, Jacob, Kostic, Ana, Li, Daniel, Kim, Yeonhee, and Siddiqi, Tanya

Abstract

Abramson: AbbVie Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, EMD Serono Inc, Genentech, Gilead Sciences Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite Pharma Inc, Merck, Novartis, Seattle Gen: Consultancy. Palomba:Kite Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Merck & Co Inc.: Consultancy; MSK (IP for Juno and Seres): Patents & Royalties; Noble Insights: Consultancy; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Seres Therapeutics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; STRAXIMM: Membership on an entity's Board of Directors or advisory committees; Evelo: Equity Ownership; Hemedicus: Speakers Bureau. Gordon:Gilead: Other: Advisory Board; Bayer: Other: Advisory Board; Juno/Celgene: Other: Advisory Board, Research Funding; Zylem LLC: Other: co-founder; research in nanoparticles in cancer. Lunning:Spectrum: Consultancy; Seattle Genetics: Consultancy; Portola: Consultancy; OncLive: Consultancy; Novartis: Consultancy; Kite: Consultancy; Gilead Sciences, Inc.: Consultancy; DAVA: Consultancy; Bayer: Consultancy; AbbVie: Consultancy; TG Therapeutics: Consultancy, Research Funding; MiRagen: Research Funding; Juno Therapeutics: Consultancy, Research Funding; Janssen Scientific Affairs, LLC: Consultancy, Research Funding; Curis: Research Funding; VANIUM: Consultancy; Verastem: Consultancy. Wang:Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Pharmacyclics: Honoraria, Research Funding; AstraZeneca: Consultancy, Honoraria, Research Funding, Speakers Bureau; MoreHealth: Consultancy, Equity Ownership; Acerta Pharma: Consultancy, Research Funding; Kite Pharma: Consultancy, Research Funding; Guidepoint Global: Consultancy; BioInvent: Consultancy, Research Funding; VelosBio: Research Funding; Loxo Oncology: Research Funding; Celgene: Honoraria, Research Funding; Juno Therapeutics: Research Funding; Aviara: Research Funding; Dava Oncology: Honoraria. Arnason:Celgene/Juno: Consultancy; Regeneron Pharmaceuticals, Inc.: Consultancy. Mehta:Pharmacyclics: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau; Spectrum: Consultancy, Speakers Bureau; Imbrium therapeutics: Consultancy; Roche-Genentech: Research Funding; Incyte: Research Funding; Kite/Gilead: Research Funding, Speakers Bureau; Takeda: Research Funding; Rhizen: Research Funding; ADC therapeutics: Research Funding; Forty Seven Inc: Research Funding; Juno/Celgene: Research Funding; Affimed: Research Funding; Seattle Genetics: Research Funding, Speakers Bureau; Astex: Research Funding; TG Therapeutics: Research Funding; miRagen: Research Funding; Kyowa-Kirin: Consultancy, Speakers Bureau; Astra-Zeneca: Speakers Bureau; Sanofi: Consultancy. Maloney:Celgene,Kite Pharma: Honoraria, Research Funding; Juno Therapeutics: Honoraria, Patents & Royalties: patients pending , Research Funding; BioLine RX, Gilead,Genentech,Novartis: Honoraria; A2 Biotherapeutics: Honoraria, Other: Stock options . Andreadis:Juno: Research Funding; Pharmacyclics: Research Funding; Genentech: Consultancy, Employment; Kite: Consultancy; Gilead: Consultancy; Jazz Pharmaceuticals: Consultancy; Roche: Equity Ownership; Novartis: Research Funding; Celgene: Research Funding; Merck: Research Funding. Sehgal:Merck: Research Funding; Juno/Celgene: Research Funding; Kite/Gilead: Research Funding. Ghosh:AstraZeneca: Honoraria, Speakers Bureau; Bristol-Myers Squibb: Honoraria, Speakers Bureau; Gilead: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Pharmacyclics LLC, an AbbVie Company: Consultancy, Honoraria, Research Funding, Speakers Bureau; SGN: Consultancy, Honoraria, Research Funding, Speakers Bureau; TG Therapeutics: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Research Funding; Genentech: Research Funding; Forty Seven Inc: Research Funding. Albertson:Juno Therapeutics, a Celgene Company: Employment, Equity Ownership. Garcia:Celgene: Employment, Equity Ownership. Kostic:Juno Therapeutics, a Celgene Company: Employment. Li:Juno Therapeutics, a Celgene Company: Employment. Kim:Juno Therapeutics, a Celgene Company: Employment. Siddiqi:TG Therapeutics: Research Funding; Kite, A Gilead Company: Research Funding; Seattle Genetics: Speakers Bureau; Janssen: Speakers Bureau; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; PCYC: Consultancy, Research Funding, Speakers Bureau; Juno Therapeutics: Consultancy, Other: travel support, Research Funding; Celgene: Research Funding; BeiGene: Research Funding.

Published
2019
Full Text
View/download PDF

20. Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Author

Bachier, Carlos R., Palomba, Maria Lia, Abramson, Jeremy S., Andreadis, Charalambos, Sehgal, Alison R., Godwin, John, Hildebrandt, Gerhard C., Siddiqi, Tanya, Stevens, Don, Farazi, Thalia, Kostic, Ana, Trede, Nikolaus S., Wang, Lei, Lymp, James, Thelen, Tennille, Ogasawara, Ken, and Maloney, David G.

Abstract

Bachier: Sanofi: Speakers Bureau; Viracyte: Consultancy; Kadmon Corporation, LLC: Consultancy. Palomba:Noble Insights: Consultancy; Pharmacyclics: Membership on an entity's Board of Directors or advisory committees; Hemedicus: Speakers Bureau; Merck & Co Inc.: Consultancy; Seres Therapeutics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; STRAXIMM: Membership on an entity's Board of Directors or advisory committees; Kite Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Evelo: Equity Ownership; MSK (IP for Juno and Seres): Patents & Royalties. Abramson:AbbVie Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, EMD Serono Inc, Genentech, Gilead Sciences Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Karyopharm Therapeutics, Kite Pharma Inc, Merck, Novartis, Seattle Gen: Consultancy. Andreadis:Roche: Equity Ownership; Novartis: Research Funding; Celgene: Research Funding; Juno: Research Funding; Pharmacyclics: Research Funding; Merck: Research Funding; Kite: Consultancy; Genentech: Consultancy, Employment; Gilead: Consultancy; Jazz Pharmaceuticals: Consultancy. Sehgal:Juno/Celgene: Research Funding; Kite/Gilead: Research Funding; Merck: Research Funding. Hildebrandt:Juno Therapeutics: Equity Ownership; crispr therapeutics: Equity Ownership; CVS Health: Equity Ownership; Immunomedics: Equity Ownership; IDEXX laboratories: Equity Ownership; Pfizer: Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Other: Travel; Cellectis: Equity Ownership; Clovis Oncology: Equity Ownership; Aetna: Equity Ownership; Bluebird Bio: Equity Ownership; Celgene: Equity Ownership; Abbvie: Equity Ownership; Cardinal Health: Equity Ownership; Johnson & Johnson: Equity Ownership; Insys Therapeutics: Equity Ownership; Axim Biotechnologies: Equity Ownership; Axim Biotechnologies: Equity Ownership; Novartis: Equity Ownership; Kite Pharma: Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Other: Travel; Sangamo: Equity Ownership; Procter & Gamble: Equity Ownership; Vertex: Equity Ownership; Bristol-Myers-Squibb: Equity Ownership; Bayer: Equity Ownership; Scotts-Miracle: Equity Ownership; Incyte: Membership on an entity's Board of Directors or advisory committees, Other: Travel; Jazz Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Research Funding; Takeda: Research Funding; Pharmacyclics: Research Funding; Astellas: Other: Travel; Endocyte: Equity Ownership; GW Pharmaceuticals: Equity Ownership; Kite Pharma: Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Other; Novartis: Equity Ownership. Siddiqi:PCYC: Consultancy, Research Funding, Speakers Bureau; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; Janssen: Speakers Bureau; Seattle Genetics: Speakers Bureau; Kite, A Gilead Company: Research Funding; TG Therapeutics: Research Funding; Celgene: Research Funding; BeiGene: Research Funding; Juno Therapeutics: Consultancy, Other: travel support, Research Funding. Stevens:Astellas: Consultancy. Farazi:Juno Therapeutics/A Celgene Company: Employment. Kostic:Juno Therapeutics, a Celgene Company: Employment. Trede:Celgene Corporation: Employment, Equity Ownership. Wang:Celgene Corporation: Employment. Lymp:Celgene Corporation: Employment, Equity Ownership. Thelen:Celgene Corporation: Employment. Ogasawara:Celgene Corporation: Employment, Equity Ownership. Maloney:Juno Therapeutics: Honoraria, Patents & Royalties: patients pending , Research Funding; Celgene,Kite Pharma: Honoraria, Research Funding; A2 Biotherapeutics: Honoraria, Other: Stock options ; BioLine RX, Gilead,Genentech,Novartis: Honoraria.

Published
2019
Full Text
View/download PDF

21. Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy

Author

Bannerji, Rajat, Advani, Ranjana H., Brown, Jennifer R., Arnason, Jon E., Barnes, Jeffrey A., Allan, John N., Ansell, Stephen M, O'Brien, Susan M., Chavez, Julio C., Adriaens, Lieve, Ufkin, Melanie, Kostic, Ana, Paccaly, Anne Josee, Gao, Bo, Lowy, Israel, Sternberg, David, and Topp, Max S.

Abstract

Introduction:REGN1979 is a CD20xCD3 bispecific antibody (Ab) based on an IgG4 isotype modified to reduce Fc binding. It is designed to bind T cells (via CD3) and CD20-expressing cells and is being evaluated for the treatment of B-lymphoid malignancies. Binding of the Ab to both targets results in specific, local T-cell activation and cytotoxicity, and this mechanism of action is distinct from that of current anti-CD20 Abs. Updated findings are presented for this open-label, multi-center, dose escalation Phase 1 trial of REGN1979 in patients (pts) with B-NHL.

Published
2017
Full Text
View/download PDF

22. Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies

Author

Topp, Max S., Borchmann, Peter, Wagner-Johnston, Nina D., Provencio, Mariano, Cordoba, Raul, Papadopoulos, Kyriakos, Martín, Alejandro, Grande, Carlos, Jagadeesh, Deepa, Lakhani, Nehal, de Vos, Sven, Mato, Anthony R., Brunnberg, Uta, Scholl, Sebastian, Pott, Christiane, Rutherford, Sarah C, Duell, Johannes, Adriaens, Lieve, Ufkin, Melanie, Kostic, Ana, Paccaly, Anne Josee, Gao, Bo, Lowy, Israel, Sternberg, David, and Carpio, Cecilia

Abstract

Introduction:Immune checkpoint inhibitors and T-cell engaging bi-specific antibodies (Abs) have shown clinical activity in lymphoid malignancies. Combinations of these agents provide promising therapeutic options in hematological diseases. Here we report findings for 69 patients (pts) with B-cell lymphoid neoplasms treated with the REGN2810 anti-PD1 Ab as a single agent or in combination with REGN1979, a CD20xCD3 bispecific full-length T-cell engaging Ab.

Published
2017
Full Text
View/download PDF

23. Intestinal Obstruction in Children

Author

Kostic, Ana, Krstic, Marijana, Slavkovic, Andjelka, and Vacic, Nikola

Abstract

Chronic abdominal pain is the most commonly seen condition in the pediatric population. Many causes can be successfully managed by conservative treatment; nevertheless, surgical intervention is sometimes inevitable. Among many surgical conditions, such as appendicitis as the most frequent cause, one is also to think about congenital abdominal bands. We report a case of a 10-year-old boy with chronic abdominal pain, who suddenly developed clinical and radiologic signs of intestinal obstruction. The cause of chronic abdominal pain as well as the intestinal obstruction was revealed during the operation: 2 congenital abdominal bands, trapping the gut convolutes. To our knowledge, this is the first report of 2 bands in a single patient.

Published
2013
Full Text
View/download PDF

24. Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

Author

Bannerji, Rajat, Brown, Jennifer R., Advani, Ranjana H, Arnason, Jon, O'Brien, Susan M., Allan, John N., Chavez, Julio C., Barnes, Jeffrey A., Joyce, Robin, Ansell, Stephen, Topp, Max S, Adriaens, Lieve, Ufkin, Melanie, Kostic, Ana, Paccaly, Anne, Gao, Bo, Trail, Pamela A., Lowy, Israel, and Brownstein, Carrie

Abstract

Brown: Acetylon, Gilead: Research Funding; Celgene, Roche/Genentech, Gilead, Infinity, Janssen, Pharmacyclics, ProNai, Sun BioPharma: Consultancy. Arnason:Gilead: Consultancy. O'Brien:Pharmacyclics, LLC, an AbbVie Company: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria. Chavez:Janssen: Speakers Bureau. Ansell:BMS, Seattle Genetics, Merck, Celldex and Affimed: Research Funding. Topp:Amgen: Consultancy, Honoraria, Other: travel, Speakers Bureau; Roche: Honoraria, Other: travel; Boehringer: Consultancy, Other: Travel, Research Funding; Jazz: Consultancy; Pfizer: Consultancy, Other: Travel. Adriaens:Regeneron Pharmaceuticals Inc.: Employment, Equity Ownership. Ufkin:Regeneron Pharmaceuticals Inc.: Employment, Equity Ownership. Kostic:Regeneron Pharmaceuticals Inc.: Employment, Equity Ownership. Paccaly:Regeneron Pharmaceuticals Inc.: Employment, Equity Ownership. Gao:Regeneron Pharmaceuticals Inc: Employment, Equity Ownership. Trail:Regeneron Pharmaceuticals Inc: Employment, Equity Ownership. Lowy:Regeneron Pharmaceuticals Inc: Employment, Equity Ownership. Brownstein:Regeneron Pharmaceuticals Inc: Employment, Equity Ownership.

Published
2016
Full Text
View/download PDF

25. A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma

Author

Fathi, Amir T, Borate, Uma, DeAngelo, Daniel J., O'Brien, Maureen M., Trippett, Tanya, Shah, Bijal D, Hale, Gregory A., Foran, James M., Silverman, Lewis B., Tibes, Raoul, Cramer, Stuart, Pauly, Melinda, Kim, Stella, Kostic, Ana, Huang, Xiaohui, Pan, Yang, and Chen, Robert

Abstract

Fathi: Exelexis: Research Funding; Agios: Membership on an entity's Board of Directors or advisory committees; Merck: Membership on an entity's Board of Directors or advisory committees; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Ariad: Consultancy; Takeda Pharmaceuticals International Co.: Research Funding. Off Label Use: SGN-CD19A is an investigational agent being studied in patients with B-cell malignancies. SGN-CD19A is not approved for use.. Borate:Seattle Genetics: Research Funding; Genoptix: Consultancy; Alexion: Speakers Bureau; Gilead: Speakers Bureau; Novartis: Speakers Bureau; Amgen: Speakers Bureau. DeAngelo:Agios: Consultancy; Incyte: Consultancy; Celgene: Consultancy; Amgen: Consultancy; Pfizer: Consultancy; Bristol Myers Squibb: Consultancy; Ariad: Consultancy; Novartis: Consultancy. O'Brien:Seattle Genetics, Inc.: Research Funding. Trippett:OSI Pharmaceuticals: Research Funding; Seattle Genetics, Inc.: Research Funding. Shah:NCCN: Consultancy; SWOG: Consultancy; Seattle Genetics: Research Funding; Acetylon Pharmaceuticals, INC: Membership on an entity's Board of Directors or advisory committees; Pharmacyclics: Speakers Bureau; Bayer: Honoraria; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Speakers Bureau; DeBartolo Institute for Personlaized Medicine: Research Funding; Rosetta Genomics: Research Funding; Plexus Communications: Honoraria; Spectrum: Speakers Bureau. Hale:Seattle Genetics, Inc.: Research Funding; Hyundai: Research Funding; V Foundation: Research Funding. Silverman:Seattle Genetics, Inc.: Research Funding. Pauly:Seattle Genetics, Inc.: Research Funding. Kim:Bayer: Consultancy; Seattle Genetics, Inc.: Consultancy, Research Funding; Eli Lilly: Consultancy. Kostic:Seattle Genetics, Inc.: Employment, Equity Ownership. Huang:Seattle Genetics, Inc.: Employment, Equity Ownership. Pan:Seattle Genetics, Inc.: Employment, Equity Ownership. Chen:Genentech: Consultancy, Speakers Bureau; Seattle Genetics, Inc.: Consultancy, Other: Travel expenses, Research Funding, Speakers Bureau; Millennium: Consultancy, Research Funding, Speakers Bureau.

Published
2015
Full Text
View/download PDF

27. Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

Author

Moskowitz, Craig H., Forero-Torres, Andres, Shah, Bijal D., Advani, Ranjana, Hamlin, Paul, Kim, Stella, Kostic, Ana, Sandalic, Larissa, Zhao, Baiteng, and Fanale, Michelle A.

Abstract

Moskowitz: Merck: Research Funding; Genentech: Research Funding; Seattle Genetics, Inc.: Consultancy, Research Funding. Off Label Use: SGN-CD19A is an investigational agent being studied in patients with B-cell malignancies. SGN-CD19A is not approved for use. . Forero-Torres:Seattle Genetics, Inc.: Research Funding, Speakers Bureau. Shah:Pharmacyclics: Speakers Bureau; SWOG: Consultancy; Celgene: Consultancy, Speakers Bureau; NCCN: Consultancy; Seattle Genetics, Inc.: Research Funding; Janssen: Speakers Bureau. Advani:Janssen Pharmaceuticals: Research Funding; Genentech: Research Funding; Pharmacyclics: Research Funding; Celgene: Research Funding; Takeda International Pharmaceuticals Co.: Research Funding; Seattle Genetics, Inc.: Research Funding, Travel expenses Other. Hamlin:Seattle Genetics, Inc.: Consultancy, Research Funding. Kim:Bayer: Consultancy; Eli Lily: Consultancy; Seattle Genetics, Inc.: Consultancy, Research Funding. Kostic:Seattle Genetics, Inc.: Employment, Equity Ownership. Sandalic:Seattle Genetics, Inc.: Employment, Equity Ownership. Zhao:Seattle Genetics, Inc.: Employment, Equity Ownership. Fanale:Seattle Genetics, Inc.: Consultancy, Honoraria, Research Funding, Travel expenses Other.

Published
2014
Full Text
View/download PDF

28. Development of Chronic Lymphocytic Leukemia (CLL) Reactive Cytotoxic T Lymphocytes after Non-Myeloablative Hematopoietic Stem Cell Transplant Correlates with Anti-Leukemia Response.

Author

Nishida, Tetsuya, Kostic, Ana, Maloney, David G., Storb, Rainer F., and Riddell, Stanley R.

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) following non-myeloablative (NM) conditioning is a promising approach for treating patients with advanced fludarabine refractory CLL. In this setting, a graft versus leukemia (GVL) effect mediated by donor T cells is critical for tumor eradication. We have evaluated the development of alloreactive and CLL-reactive cytotoxic T lymphocyte (CTL) responses in patients after NM-HSCT to determine if the generation of detectable T cell responses was associated with an antitumor response. Seven patients with fludarabine refractory CLL were conditioned with fludarabine (30mg/m2 x 3 doses) and total body irradiation (2 Gy) prior to receiving G-CSF mobilized peripheral blood stem cells from an HLA matched donor. Peripheral blood mononuclear cells (PBMC) were obtained from the recipient pretransplant and at intervals after NM-HSCT. When chimerism showed a major proportion of donor CD3+ T cells, the postransplant PBMC were stimulated in vitro with recipient CLL cells from the pretransplant collections. CLL cells lack or express low levels of co-stimulatory and adhesion molecules, and are poor stimulators of T cells in vitro. Thus, prior to their use as stimulators and targets, the CLL cells were activated with CD40 ligand (CD40L), which upregulates costimulatory, adhesion, and MHC molecule expression, and turns CLL cells into effective antigen presenting cells. The cultures were stimulated weekly and supplemented with IL2 and IL7. After two stimulations, the T cell lines were tested for cytotoxicity against donor and recipient target cells including recipient CLL. T cell lines generated from four patients with a good antitumor response after NM-HSCT exhibited cytotoxicity against recipient CLL and EBV transformed B cells (B-LCL), but not against donor B-LCL. By contrast, T cell lines generated from three patients with persistent or progressive disease after NM-HSCT did not have cytotoxicity against recipient CLL, despite the development of GVHD in all patients. Multiparameter flow cytometry and IFN-g secretion assay of T cell lines from patients with an antitumor response showed that both CD8+ and CD4+ T cells produced INF-g in response to recipient CLL. We sorted and expanded CD8+ INF-g+ and CD4+ IFN-g+ T cells and both subsets were able to lyse CLL cells. The cytotoxicity of CD4+ and CD8+ T cells was inhibited completely by concanamycin A, suggesting perforin is the major mechanism for leukemia cell lysis. Twenty-one CD8+ T cell clones specific for distinct minor histocompatibility antigens expressed on CLL were isolated from T cell lines of the four responding patients. Multiple specificities were recognized in three of the four patients. Screening a cDNA expression library has identified the genes encoding two minor histocompatibility antigens recognized by CD8+ T cells, and their characterization is in progress. These findings suggest that the development after NM-HSCT of early, diverse, alloreactive T cell responses specific for antigens expressed by CLL may be an important predictor of outcome. The identification of the antigens recognized may facilitate the development of strategies to evoke an effective antitumor response in a larger fraction of patients.

Published
2006
Full Text
View/download PDF

29. Researcher at University of Belgrade Reports Research in Food Research (Broccoli, Amaranth, and Red Beet Microgreen Juices: The Influence of Cold-Pressing on the Phytochemical Composition and the Antioxidant and Sensory Properties).

Subjects
BEETS, BROCCOLI, FOOD research, RESEARCH personnel, AMARANTHS, ANTIOXIDANTS
Abstract

A recent study conducted at the University of Belgrade analyzed the phytochemical composition, antioxidant properties, and sensory characteristics of amaranth, red beet, and broccoli microgreens and their cold-pressed juices. The study found that all samples contained various phenolic compounds, with betalains present in amaranth and red beet microgreens, and glucosinolates detected only in broccoli microgreens. Cold-pressing the microgreens into juice altered the profiles of bioactive compounds, with isothiocyanates found in broccoli juice and phenolic acid aglycones and derivatives identified in all juices. The microgreen juices exhibited good antioxidant properties and were well-accepted in terms of taste and quality. The researchers concluded that these cold-pressed microgreen juices could be considered novel functional products due to their rich source of bioactive compounds. [Extracted from the article]

Published
2024

30. "Methods For Treating Eosinophilic Esophagitis By Administering An Il-4r Inhibitor" in Patent Application Approval Process (USPTO 20230272085).

Subjects
PATENT applications, EOSINOPHILIC esophagitis, DIGESTIVE system diseases, PATENT offices, THERAPEUTICS, RESPIRATORY diseases, PERIOSTIN
Abstract

The method of claim 69, wherein the atopic disease is food allergy, atopic dermatitis, asthma, allergic rhinitis, or allergic conjunctivitis. The following quote was obtained by the news editors from the background information supplied by the inventors: "Eosinophilic esophagitis (EoE) is an emerging disease characterized by esophageal dysfunction and by abnormal eosinophilic inflammation of the esophagus. [Extracted from the article]

Published
2023

31. 'Combination Therapy Using A Liv1-Adc And A Chemotherapeutic' in Patent Application Approval Process (USPTO 20190085091)

Subjects
Seagen Inc. -- Intellectual property, Carboplatin -- Intellectual property, Biological products industry -- Intellectual property, Women -- Health aspects, Biotechnology industry -- Intellectual property, Pertuzumab, Chemotherapy, Cancer -- Chemotherapy, Health, Women's issues/gender studies
Abstract

2019 APR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- A patent application by the inventors Sussman, Django (Seattle, WA); Li, Fu (Bothell, WA); [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results